

IMAGION BIOSYSTEMS LIMITED

(ASX: IBX)

19 October 2020

Imagion Biosystems appoints Geoff Hollis as CFO

MELBOURNE — Imagion Biosystems Limited (ASX: IBX), a company dedicated to improving healthcare through the earlier detection of cancer, has appointed Geoff Hollis as Chief Financial Officer. The appointment strengthens the Company's management and leadership team as the Company moves into its next phase of growth to develop and commercialize its medical device technology to non-invasively detect cancer.

Geoff, based in Melbourne, takes up his position as Imagion CFO on 1 December 2020.

Geoff has served as the Chief Financial Officer for multiple ASX listed companies, including Lifestyle Communities where he played a key role in cash management and financing to facilitate rapid growth, reaching the ASX300 and creating significant shareholder value. Geoff's career in finance began with 10 years at Pitcher Partners a top ten national accounting and financial advisory firm.

Imagion's executive chairman and CEO, Bob Proulx, said Geoff is a welcome addition to Imagion's executive management team. Being based in Australia, Geoff will be well positioned to assist with the Company's developing business interests in Australia and will be closer to the Company's investors and the capital markets to facilitate investor relations.

"We look forward to having Geoff aboard as the Company moves through its next growth phase and as we plan to advance the business beyond our upcoming MagSense™ HER2 Phase I study for metastatic breast cancer," Mr Proulx said.

"Geoff has had great experience in corporate transformation, growth strategies, capital raising, capital management, attracting institutional investors and general investor relations. We expect that will be of significant benefit to Imagion as we enter an exciting phase of our business and work to maximise shareholder value."

Geoff replaces Brian Conn, who served as Imagion's part-time CFO since 2017 and who left Imagion in August to take up a full-time CFO position with another of his clients.

-ENDS

About Imagion Biosystems

Imagion Biosystems is developing a new non-radioactive and safe diagnostic imaging technology. Combining biotechnology and nanotechnology, the Company aims to detect cancer and other diseases earlier and with higher specificity than is currently possible. Imagion Biosystems listed on the Australian Securities Exchange (ASX) in June 2017.

For further information please visit www.imagionbiosystems.com

Authorisation & Additional information

This announcement was authorised by the Disclosure Committee of Imagion Biosystems Limited



U.S. Media Contact:

Matthew Wygant

matthew@biotechwriting.com

+1-408-905-7630

Australian Media & Investor Relations:

Kyahn Williamson, WE Communications

We-AUImagionBiosystems@we-worldwide.com

+61 (0) 401018828

Imagion Biosystems Limited

ACN 616 305 027

Level 25, 525 Collins Street, Melbourne VIC 3000

www.imagionbiosystems.com